NPH insulin
Prijeđi na navigaciju
Prijeđi na pretragu
| NPH insulin | |
|---|---|
| |
| Drugi nazivi | Humulin N, Humulin N Pen, Humulin® N, Novolin N |
| Identifikacija | |
| CAS registarski broj | 53027-39-7 
|
| DrugBank | DB08914 |
| ATC code | A10 |
| Farmakologija | |
| Načini upotrebe | Subkutano |
|
Ukoliko nije drugačije napomenuto, podaci se odnose na standardno stanje (25 °C, 100 kPa) materijala | |
| Infobox references | |
NPH insulin (neutralni protaminski Hagedorn, izofanski insulin) brzodelujući je insulin koji se koristi za poboljšanje glicemijske kontrole. On se proizvodi pomoću genetički modifikovane bakterije Escherichia coli. Ljudska suspenzija insulina izofana se sastoji od kristaline suspenzije ljudskog insulina sa protaminom i cinkim. Tak kombinaci daje intermedijarno delujući insulin sa sporijim početkom dejstva i dužim trajanjem od normalnog ljudskog insulina.[1][2][3][4][5][6]
Reference[uredi | uredi kod]
- ↑ Lepore M, Pampanelli S, Fanelli C, Porcellati F, Bartocci L, Di Vincenzo A, Cordoni C, Costa E, Brunetti P, Bolli GB: Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes. 2000 Dec;49(12):2142-8. PMID 11118018
- ↑ Owens DR, Coates PA, Luzio SD, Tinbergen JP, Kurzhals R: Pharmacokinetics of 125I-labeled insulin glargine (HOE 901) in healthy men: comparison with NPH insulin and the influence of different subcut aneous injection sites. Diabetes Care. 2000 Jun;23(6):813-9. PMID 10841002
- ↑ Danne T, Lupke K, Walte K, Von Schuetz W, Gall MA: Insulin detemir is characterized by a consistent pharmacokinetic profile across age-groups in children, adolescents, and adults with type 1 diabetes. Diabetes Care. 2003 Nov;26(11):3087-92. PMID 14578244
- ↑ Owens DR, Bolli GB: Beyond the era of NPH insulin--long-acting insulin analogs: chemistry, comparative pharmacology, and clinical application. Diabetes Technol Ther. 2008 Oct;10(5):333-49. doi: 10.1089/dia.2008.0023. PMID 18715209
- ↑ Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS (2011). „DrugBank 3.0: a comprehensive resource for omics research on drugs”. Nucleic Acids Res. 39 (Database issue): D1035-41. DOI:10.1093/nar/gkq1126. PMC 3013709. PMID 21059682.
- ↑ David S. Wishart, Craig Knox, An Chi Guo, Dean Cheng, Savita Shrivastava, Dan Tzur, Bijaya Gautam, and Murtaza Hassanali (2008). „DrugBank: a knowledgebase for drugs, drug actions and drug targets”. Nucleic Acids Res 36 (Database issue): D901-6. DOI:10.1093/nar/gkm958. PMC 2238889. PMID 18048412.
Literatura[uredi | uredi kod]
- Baganz, H. M.; Carfagno, S. C.; Cowan, B. Y.; Dillon, E. S. (1951). „NPH insulin; its comparison with previous insulin regimens”. The American journal of the medical sciences 222 (1): 1–6. PMID 14846799.
- Burnham, D. K. (1951). „Insulin and insulin mixtures; nph insulin”. California medicine 75 (6): 412–415. PMC 1521099. PMID 14886746.
- Lacey, A. H. (1952). „A comparison of preparations of NPH insulin”. The Journal of pharmacology and experimental therapeutics 105 (2): 196–202. PMID 14928221.
- Deckert, T.; Hansen, B.; Kølendorf, K.; Poulsen, J. S.; Smith, M. (1982). „Absorption of NPH-insulin from subcutaneous tissue: A methodological study in pigs”. Acta pharmacologica et toxicologica 51 (1): 30–37. PMID 6751023.
- Kølendorf, K.; Bojsen, J. (1982). „Kinetics of subcutaneous NPH insulin in diabetics”. Clinical pharmacology and therapeutics 31 (4): 494–500. PMID 7060331.
